Dry Powder Inhalation of Particles Containing Anti-tuberculosis Drugs
Implementing Organization
Central Research Institute (CRI)
Central Drug Research Institute (CDRI)
About
Treatment of pulmonary TB with orally-administered drugs is sub-optimal-exposing non-target tissues to toxic drugs and requiring large doses to build up effective concentrations in lungs
. Prolonged dosing is required to build up and maintain effective concentrations in lungs
. Patients remain infectious for considerable periods after initiating drug treatment.
Patents
ZA200603256
Outcome / Output
It is safe and helps is reducing drug intake over time thereby reducing duration of treatment.
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Central Research Institute (CRI)
Acces sibility Controls